Biotech News

PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

PureTech Health (PRTC)PureTech Health2026-04-27 11:05 ESTCompany update

RNS Number: 9985B PureTech Health PLC 27 April 2026 27 April 2026 PureTech Health plc PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (" PureTech " or the

PureTech Health

Founded-Entity Model PureTech Health creates and advances biotechnology companies around internally identified scientific concepts. Rather than operating as a conventional single-pipeline developer, it retains ownership interests and economic rights across a portfolio of independently financed founded entities. Celea Therapeutics Celea...

Recent company news

PRTCPureTech Health2026-07-13 06:00 EST

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

PRTCPureTech Health2026-07-02 06:01 EST

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PRTCPureTech Health2026-07-02 06:00 EST

PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PRTCPureTech Health2026-06-10 16:38 EST

Results of Annual General Meeting

PRTCPureTech Health2026-06-09 06:00 EST

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Stock data

Close: 17.42 USD
Market cap: 424.03M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

Related news

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering

PureTech Health

Recent company news

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

Results of Annual General Meeting

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Stock data

PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

Related news

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering

PureTech Health

Recent company news

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

Results of Annual General Meeting

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Stock data

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)